Boston Scientific receives FDA clearance for next generation SpyGlass direct visualization system

Boston Scientific received FDA 510(k) clearance for its SpyGlass DS Direct Visualization System.

Advertisement

The system is cleared for use in the diagnosis and treatment of pancreatico-biliary disease. The first cases involving use of the system were cholangioscopy and pancreatoscopy procedures. The system is built on the technology of the original SpyGlass System, and aims to optimize procedural efficiency and productivity.

More articles on GI/endoscopy:

GI physician leader to know: Dr. Anthony DiMarino of Jefferson University Hospitals
Boston Scientific SVP sold 11k+ shares: 4 things to know
APIC, SHEA address infections linked to duodenscopes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.